Announcement on Obtaining Acceptance Notice for IND Application of Innovative Drug HSK51155 Tablets

Haisco Pharmaceutical Group Co., Ltd.·June 9, 2026·2 pages

✨ AI Summary

Hansoh Pharmaceutical Group Company Limited announces it has received an acceptance notice from the NMPA for the IND application of its innovative drug HSK51155 tablets. The drug is a Class 1 chemical drug, a non-opioid analgesic. The company has also entered a collaboration with AbbVie for global rights outside China, with potential transaction value exceeding $700 million.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Securities Code: 002653 Securities Abbreviation: Hansoh Announcement No.: 2026-060

Hansoh Pharmaceutical Group Co., Ltd. Announcement on Obtaining Acceptance Notice for IND Application of Innovative Drug HSK51155 Tablets

The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and that there are no false records, misleading statements, or major omissions.

Hansoh Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") recently received an "Acceptance Notice" issued by the National Medical Products Administration, the basic situation is as follows:

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.